Merck's Erbitux receives EC approval for head & neck cancer
Tuesday, December 02, 2008 09:00 IST Darmstadt
Merck KGaA and its Merck Serono division announced that it has received approval from the European Commission to extend the use of its targeted therapy Erbitux (cetuximab) to include first-line treatment of patients
